Tests TH9619 in adults with advanced solid tumors
Tests the drug TH9619 in adults with advanced solid cancers.
Plain-language title generated from the registry record
Registry title: Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Key facts
- Where
- Barcelona and Madrid, SpainSee the 2 sites
- Phase
- Phase 1/2
Where in Spain
- Vall d'Hebron Institute of OncologyBarcelona, SpainTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- One-carbon Therapeutics AB
- Trial code
- NCT07151040EU 2024-519639-40-00
- Record updated
- 28 January 2026
- Original description
This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.Read full original descriptionShow less
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation, Confirmation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of TH9619 in Subjects With Advanced Solid Tumors
This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.
Inclusion: Must have given written informed consent; Histopathologically confirmed advanced cancer (colorectal cancer, head and neck squamous cell cancer, non-small cell lung cancer and gastric cancer (including gastroesophageal junction cancer)); Prior treatment with at least one line of cytotoxic systemic therapy for metastatic/unresectable cancer; Adult patients (≥18 years of age); Must be willing to comply with study procedures.
Exclusion: History or presence of any clinically significant disorders as judged by the Investigator.